Inclusion Criteria:  Subject is 20 to 70 years of age at time of screening Subject's weight is between 50 and 120 kg A clinical diagnosis of Type 1 diabetes as determined by the Investigator for a minimum of 36 months prior to enrollment Subject has ongoing use of an insulin pump and rtCGM ≥ 6 months prior to screening current use of 670G 4.0 pump Subject has an A1C value ≤ 10.0% demonstrated at the time of enrollment. Subject uses a rapid-acting analogue insulin in his/her pump Patient is willing to undergo all study procedures English proficiency Minimum daily insulin requirement (Total Daily Dose) of greater than or equal to 8 units  Exclusion Criteria:  Female subject who has a positive serum pregnancy screening test, or who plans to become pregnant during the course of the study Subject has unresolved adverse skin condition, or unable to tolerate tape adhesive, in the area of sensor placement or device replacement (e.g., psoriasis, rash, Staphylococcus infection) Subject has a history of hypoglycemic seizure or hypoglycemic coma within the past 12 months Subjects currently taking adjunct therapy with SGLT2-inhibitors, Amylin. Subject has a history of seizure disorder unrelated to diabetes within the past 12 months Gastroparesis, uncontrolled thyroid disorder, Addison disease,. , Pituitary insufficiency Subject has a history of myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack (TIA), cerebrovascular accident (CVA), congestive heart failure, ventricular rhythm disturbances, or thromboembolic disease within the past 6 months Subject has a presence of a cardiac pacemaker or any other device that may be sensitive to radio frequency telemetry Subject has any condition, including screening lab values that in the opinion of the Investigator may preclude him/her from participating in the study and completing study related procedures Subject is actively participating in other investigational study (drug or device) Subjects who consume alcohol daily Use of CGM (other than per protocol) throughout the duration of the study Use of Hydroxyurea medication